Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression

N Joshi, F Hajizadeh, EA Dezfouli, AO Zekiy, MN Afjadi… - Life sciences, 2021 - Elsevier
Aims Despite extensive efforts to find new treatments, chemotherapy is still one of the first
and foremost choices for cancer treatment. The main problems of using these drugs are the …
被引用次数：31 相关文章

Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression

N Joshi, F Hajizadeh, EA Dezfouli, AO Zekiy… - Life …, 2021 - pubmed.ncbi.nlm.nih.gov
Aims Despite extensive efforts to find new treatments, chemotherapy is still one of the first
and foremost choices for cancer treatment. The main problems of using these drugs are the …
[PDF] google.com

[PDF][PDF] Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression

N Joshi, F Hajizadeh, EA Dezfouli, AO Zekiy… - Life …, 2021 - drive.google.com
Aims: Despite extensive efforts to find new treatments, chemotherapy is still one of the first
and foremost choices for cancer treatment. The main problems of using these drugs are the …

Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression.

N Joshi, F Hajizadeh, AO Zekiy, SM Mousavi… - Life …, 2021 - europepmc.org
Aims Despite extensive efforts to find new treatments, chemotherapy is still one of the first
and foremost choices for cancer treatment. The main problems of using these drugs are the …

Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression

N Joshi, F Hajizadeh, SM Mousavi, V Karpisheh… - Life Sciences, 2021 - elibrary.ru
We would like to thank Tabriz University of Medical Sciences (grant number: 65881) and the
National Institute for Medical Research Development, NIMAD (grant number: 989658) for …

[引用][C] Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression

N Joshi, F Hajizadeh, EA Dezfouli, AO Zekiy, MN Afjadi… - 2021